Report Categories
View AllRecent Articles
View All
Jim Cramers Market Commentary Highlights Potential Opportunities and Caution
US AI Expansion in Asia Gains Momentum Following TrumpXi Summit
Qualcomm Stock Surges as AI Device Boom Gains Investor Attention
Duke Energy Price Target Reduced by 5 Amid Market Adjustments
Jim Cramer Advises Holding Astera Labs Shares Amid Market Uncertainty
GM Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response
BPRN Q1 2026 Earnings Strong EPS Beat Lifts Shares as Princeton Bancorp Delivers 091
American Realty Investors Inc Q3 2024 Earnings Negative EPS of 108 as Losses Persist Stock Declines
Textron Q1 2026 Earnings EPS Beat Driven by Strong Operational Performance
LARK Q1 2026 Earnings EPS of 083 Amidst Stock Decline
Nuveen Select Maturities Municipal Fund NIM Holds Steady at 928 as Consolidation Persists
Vita Coco Company Inc COCO Sees Uptick as Shares Rise 28 Key Levels in Focus
Energous Corporation WATT Edges Higher as Stock Tests Key Resistance Levels
Entergy Louisiana Bond ELC Holds Steady Near 2032 as Yield Environment Shifts
Prediction Markets Spark Legal Clash Between State Regulators and Federal Authorities
SBILed Consortium Invites Bids for Essar Group Promoter Guarantees with Rs 200 Crore Reserve Price
Tesla CEO Musk Points to China as Key Rival in Humanoid Robot Development
Thai Conglomerate CP Group Confronts Internal Strife Over Financial Services Unit
External Links
AU Real Estate Plans Rs 1200 Crore Housing Project in Ghaziabad
SPH Q1 2026 Earnings Earnings Beat Drives Modest Stock Uptick
RELL Q1 2026 Earnings EPS Surges Past Estimates Amid Mixed Market Sentiment
Enbridge ENB Q1 2026 Earnings Solid Earnings Beat Driven by Operational Strength
MX Q1 2026 Earnings NarrowerThanExpected Loss Drives Stock Rally
CELH Q1 2026 Earnings EPS Surges 355 Above Estimates Driving Stock Higher
CHA Q4 2025 Earnings Massive EPS Miss Sends Shares Lower
Strategy Inc MSTR Q1 2026 Earnings Massive EPS Miss as Digital Asset Impairments Deepen Losses
SSYS Q1 2026 Earnings Beats EPS Estimates on Surprise Profitability
DRMA Q1 2026 Earnings NarrowerthanExpected Loss Marks Progress for ClinicalStage Biotech